QDEL · Quidelortho Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $619.80M | - | $699.90M | $613.90M | $692.80M | - | $727.10M | $637.00M | $711.00M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $44.90M | - | $41.50M | $45.70M | $53.20M | - | $55.90M | $56.30M | $59.20M | - |
| SG&A | $199.30M | - | $186.90M | $178.00M | $187.00M | - | $186.40M | $188.20M | $204.70M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $112.90M | - | $112.10M | $110.30M | $107.10M | - | $113.10M | $116.10M | $114.90M | - |
| Operating Income | ($31.80M) | - | ($704.80M) | ($180.70M) | $32.60M | - | $15.00M | ($117.50M) | ($1.76B) | - |
| Interest Expense | $51.10M | - | $46.10M | $41.00M | $40.00M | - | - | - | - | - |
| Income Tax | $12.30M | - | ($23.90M) | $25.80M | $3.90M | - | ($8.90M) | ($15.20M) | ($92.90M) | - |
| Net Income | ($91.80M) | - | ($733.00M) | ($255.40M) | ($12.70M) | - | ($19.90M) | ($147.70M) | ($1.71B) | - |
| EPS - Basic | ($1.35) | - | ($10.78) | ($3.77) | ($0.19) | - | ($0.30) | ($2.20) | ($25.50) | - |
| EPS - Diluted | ($1.35) | - | ($10.78) | ($3.77) | ($0.19) | - | ($0.30) | ($2.20) | ($25.50) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $140.40M | $169.80M | $98.10M | $151.70M | $127.10M | $98.30M | $143.70M | $107.00M | $78.50M | $118.90M |
| Accounts Receivable | $359.90M | $417.00M | $386.50M | $275.00M | $286.00M | $282.40M | $294.90M | $269.50M | $271.70M | $303.30M |
| Inventory | $611.50M | $577.60M | $613.80M | $578.70M | $563.20M | $533.70M | $577.00M | $602.00M | $583.10M | $577.80M |
| Accounts Payable | $243.50M | $279.40M | $213.70M | $218.80M | $230.90M | $246.00M | $247.20M | $237.40M | $249.60M | $294.80M |
| Current Assets | $1.38B | $1.45B | $1.37B | $1.28B | $1.26B | $1.22B | $1.41B | $1.34B | $1.21B | $1.31B |
| Total Assets | $5.63B | $5.77B | $5.68B | $6.38B | $6.46B | $6.42B | $6.80B | $6.69B | $6.70B | $8.56B |
| Current Liabilities | $962.40M | $966.10M | $767.90M | $1.14B | $1.05B | $998.80M | $1.03B | $932.40M | $779.80M | $833.80M |
| Long-term Debt | - | $2.70B | - | - | - | $2.49B | - | - | - | $2.42B |
| Total Liabilities | $3.78B | $3.85B | $3.64B | $3.59B | $3.46B | $3.44B | $3.61B | $3.52B | $3.40B | $3.56B |
| Stockholders' Equity | $1.85B | $1.92B | $2.04B | $2.79B | $3.00B | $2.98B | $3.19B | $3.17B | $3.31B | $5.01B |
| Retained Earnings | ($1.09B) | ($996.00M) | ($865.30M) | ($132.30M) | $123.10M | $135.80M | $314.20M | $334.10M | $481.80M | $2.19B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($33.00M) | - | - | - | $65.60M | - | - | - | ($700.0K) | - |
| Investing Cash Flow | ($34.00M) | - | - | - | ($56.20M) | - | - | - | ($20.20M) | - |
| Financing Cash Flow | $37.60M | - | - | - | $17.60M | - | - | - | ($18.50M) | - |
| CapEx | $34.00M | - | - | - | $56.20M | - | - | - | $66.10M | - |
| Free Cash Flow | ($67.00M) | - | - | - | $9.40M | - | - | - | ($66.80M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -5.1% | - | -100.7% | -29.4% | 4.7% | - | 2.1% | -18.4% | -247.3% | - |
| EBITDA margin | 13.1% | - | -84.7% | -11.5% | 20.2% | - | 17.6% | -0.2% | -231.1% | - |
| Net margin | -14.8% | - | -104.7% | -41.6% | -1.8% | - | -2.7% | -23.2% | -239.9% | - |
| Free cash flow margin | -10.8% | - | - | - | 1.4% | - | - | - | -9.4% | - |
| FCF / Net income | 0.73 | - | - | - | -0.74 | - | - | - | 0.04 | - |
| R&D / Revenue | 7.2% | - | 5.9% | 7.4% | 7.7% | - | 7.7% | 8.8% | 8.3% | - |
| SG&A / Revenue | 32.2% | - | 26.7% | 29.0% | 27.0% | - | 25.6% | 29.5% | 28.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1.6% | - | -12.9% | -4.0% | -0.2% | - | -0.3% | -2.2% | -25.5% | - |
| Return on equity | -5.0% | - | -36.0% | -9.1% | -0.4% | - | -0.6% | -4.7% | -51.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.43 | 1.50 | 1.78 | 1.12 | 1.20 | 1.22 | 1.38 | 1.44 | 1.55 | 1.57 |
| Quick ratio | 0.80 | 0.90 | 0.98 | 0.62 | 0.66 | 0.69 | 0.81 | 0.79 | 0.81 | 0.88 |
| Cash ratio | 0.15 | 0.18 | 0.13 | 0.13 | 0.12 | 0.10 | 0.14 | 0.11 | 0.10 | 0.14 |
| Leverage | ||||||||||
| Debt / Equity | - | 1.40 | - | - | - | 0.83 | - | - | - | 0.48 |
| Debt / Assets | - | 0.47 | - | - | - | 0.39 | - | - | - | 0.28 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.6x | - | -15.3x | -4.4x | 0.8x | - | - | - | - | - |
| Equity multiplier | 3.04 | 3.00 | 2.79 | 2.28 | 2.16 | 2.15 | 2.13 | 2.11 | 2.03 | 1.71 |
| Liabilities / Assets | 0.67 | 0.67 | 0.64 | 0.56 | 0.54 | 0.54 | 0.53 | 0.53 | 0.51 | 0.42 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.12 | 0.10 | 0.11 | - | 0.11 | 0.10 | 0.11 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 212d | - | 202d | 164d | 151d | - | 148d | 154d | 139d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.5x | - | 0.9x | 0.7x | 0.8x | - | 1.0x | 0.7x | 1.0x | - |
| P / S | 1.6x | - | 2.8x | 3.2x | 3.4x | - | 4.2x | 3.5x | 4.5x | - |
| EV / EBITDA | 10.7x | - | - | - | 15.9x | - | 22.8x | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -10.5% | - | -3.7% | -3.6% | -2.6% | - | -2.3% | -4.2% | -16.0% | - |
| Revenue CAGR (3y) | -9.9% | - | 11.1% | 0.0% | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | -53.8% | - | - | -43.0% | -336.8% | - | - |
| Net income growth (YoY) | -622.8% | - | -3583.4% | -72.9% | 99.3% | - | -56.7% | -177.6% | - | - |
| EPS growth (YoY) | -610.5% | - | -3493.3% | -71.4% | 99.3% | - | -57.9% | -175.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -38.2% | -35.7% | -36.1% | -12.0% | -9.4% | -40.4% | -35.8% | -36.6% | -33.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-28.
Business segments
$2.73B totalNorth America Segment$1.49B · 54.5%
EMEASegment$360.70M · 13.2%
China Segment$334.70M · 12.3%
JPACSegment$293.00M · 10.7%
Latin America Segment$252.90M · 9.3%
Geographic
$2.73B totalDomestic Country$1.44B · 52.6%
Foreign Country$1.29B · 47.4%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing QuidelOrtho Corp against the 5 most active filers in the same SIC group.